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Abstract 
BACKGROUND In time-to-first-event analyses, icosapent ethyl significantly reduced the risk 
of ischemic events, including cardiovascular death, among patients with elevated triglycerides 
receiving statins. These patients are at risk for not only first but also subsequent ischemic events. 
OBJECTIVES Pre-specified analyses determined the extent to which icosapent ethyl reduced 
total ischemic events. 
METHODS The Reduction of Cardiovascular Events with EPA-Intervention Trial (REDUCE-
IT) randomized 8,179 statin-treated patients with triglycerides ≥135 and <500 mg/dL (median 
baseline of 216 mg/dL) and LDL-cholesterol >40 and ≤100 mg/dL (median baseline of 75 
mg/dL), and a history of atherosclerosis (71% patients) or diabetes (29% patients) to icosapent 
ethyl 4g/day or placebo. The main outcomes were total (first and subsequent) primary composite 
endpoint events (cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, coronary 
revascularization, or hospitalization for unstable angina) and total key secondary composite 
endpoint events (cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke). As a 
pre-specified statistical method, we determined differences in total events using negative 
binomial regression. We also determined differences in total events using other statistical 
models, including Andersen-Gill, Wei-Lin-Weissfeld (Li and Lagakos modification), both pre-
specified, and a post hoc joint-frailty analysis.  
RESULTS In 8,179 patients, followed for a median of 4.9 years, 1,606 (55.2%) first primary 
endpoint events and 1,303 (44.8%) subsequent primary endpoint events occurred (which 
included 762 second events, and 541 third or more events). Overall, icosapent ethyl reduced total 
primary endpoint events (61 versus 89 per 1000 patient years for icosapent ethyl versus placebo, 
respectively; RR 0.70, 95% CI 0.62-0.78, P<0.0001). Icosapent ethyl also reduced each 
component of the primary composite endpoint, as well as the total key secondary endpoint events 
(32 versus 44 per 1000 patient years for icosapent ethyl versus placebo, respectively, RR 0.72, 
95% CI 0.63-0.82, P<0.0001).  
CONCLUSIONS Among statin-treated patients with elevated triglycerides and cardiovascular 
disease or diabetes, multiple statistical models demonstrate that icosapent ethyl substantially 
reduces the burden of first, subsequent, and total ischemic events. 
TRIAL REGISTRATION clinicaltrials.gov identifier: NCT01492361 
 
Keywords: Icosapent ethyl, eicosapentaenoic acid  
 
Condensed Abstract: The results of analyses by multiple statistical models presented here for 
REDUCE-IT (median follow-up of 4.9 years) demonstrate that icosapent ethyl 4 grams daily 
significantly reduced the rate of total primary endpoint events (RR 0.70, 95% CI 0.62-0.78, 
P<0.0001), each primary endpoint component, including cardiovascular death, and total key 
secondary endpoint events in statin-treated patients with elevated triglycerides and established 
cardiovascular disease or diabetes at risk for not only first but also subsequent ischemic events.  
 
Abbreviations 
CEC = Clinical Endpoint Committee 
CI = confidence interval 
CRP = C-reactive protein 
EPA = eicosapentaenoic acid 
HR = hazard ratio 
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LDL = low density lipoprotein 
MI = myocardial infarction 
REDUCE-IT = Reduction of Cardiovascular Events with EPA - Intervention Trial 
TG = Triglyceride 
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Despite the tremendous advance of statin therapy in secondary and primary prevention, 
ischemic events continue to occur in patients with cardiovascular risk factors such as elevated 
triglycerides, atherosclerosis, or diabetes (1-4). In addition to their initial events, such patients 
are at substantial risk for recurrent, potentially fatal events. Assessment of these recurrent events 
provides a perspective on the total atherosclerotic event burden these patients face (5-11). From a 
patient’s perspective (and also for physicians and payors), it is not only first events that are 
important, but subsequent events as well. 
One marker of this residual cardiovascular risk that predisposes patients to initial and 
recurrent ischemic events is elevated triglyceride levels (12,13). Multiple epidemiologic and 
genetic analyses have demonstrated an independent association with increased cardiovascular 
risk (14). Among several properties, icosapent ethyl reduces triglyceride levels and other lipids 
and lipoproteins without increasing LDL-cholesterol when compared with placebo and has also 
been reported to have anti-inflammatory and plaque stabilizing properties, as well as stabilizing 
effects on cell membranes (15-19). Recently, icosapent ethyl has been demonstrated to reduce 
the first occurrence of the primary composite endpoint of cardiovascular death, nonfatal 
myocardial infarction, nonfatal stroke, coronary revascularization, or hospitalization for unstable 
angina in the Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial 
(REDUCE-IT), with a 25% relative risk reduction and a 4.8% absolute risk reduction (number 
needed to treat [NNT] of 21) (20). The time to first occurrence of the key secondary composite 
endpoint of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke was also 
reduced with icosapent ethyl, with a 26% relative risk reduction and a 3.6% absolute risk 
reduction (NNTof 28). The results were also consistent across each of the primary and key 
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secondary endpoint components and appear to be applicable to a substantial proportion of 
patients in clinical practice (21). 
We sought to determine the impact of icosapent ethyl on total ischemic events (first and 
subsequent events) to characterize better the totality of the ischemic event burden across the 
overall study population. 
Methods 
Study design and participants 
The details of the REDUCE-IT design have been previously published (22). Briefly, patients 
were randomized in a double-blind manner to icosapent ethyl 4 g/day (2 grams twice daily with 
meals) or placebo (Online Figure 1, Online Figure 2). Approximately 1,612 events were 
projected necessary for 90% power to detect a 15% relative risk reduction after accounting for 
two protocol pre-specifed interim analyses (final two-sided alpha level = 0.0437).  This resulted 
in a target patient population of approximately 7,990 patients. Among all randomized patients, 
70.7% were enrolled on the basis of secondary prevention and 29.3% for primary prevention. 
Patients were randomized to one of two treatment arms on a 1:1 ratio using a computer-
generated randomization schema. Study medication and placebo capsules were similar in size 
and appearance to maintain blinding. Randomization was stratified according to cardiovascular 
risk cohort (secondary or primary prevention), use of ezetimibe (yes/no), and by geographical 
region (Westernized, Eastern European, and Asia Pacific countries). There were 473 sites in 11 
countries randomizing patients from 2011 to 2016. The protocol was submitted to and approved 
by appropriate health authorities, ethics committees, and institutional review boards. Trial 
completion occurred after achieving the approximate number of pre-specified necessary events. 
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To be eligible, patients were required to be either ≥45 years of age with established 
cardiovascular disease (secondary prevention stratum) or ≥50 years old with type 2 or type 1 
diabetes mellitus requiring treatment with medication, and to have at least one additional 
cardiovascular risk factor (primary prevention stratum) (21,22). 
Patients had fasting triglycerides of ≥135 mg/dL and <500 mg/dL and LDL-cholesterol 
>40 mg/dL and ≤100 mg/dL. The initial version of the protocol permitted a 10% variance in the 
lower qualifying triglyceride levels of ≥150 mg/dL, therefore patients with triglycerides ≥135 
mg/dL were randomized. After approximately 60% of the patients were enrolled, an amendment 
increased the lower limit of permissible triglyceride levels to 200 mg/dL with no variability 
allowance. The study included 841 (10.3%) patients with baseline triglyceride levels < 150 
mg/dL. Patients were required to be on stable statin therapy for ≥ four weeks with well-
controlled LDL-C to investigate the potential benefit of icosapent ethyl 4g/day beyond the 
current standard of care. Additional inclusion and exclusion criteria published previously (22) 
are provided in the online appendix.  
After randomization, follow-up visits continued at 4 months, 12 months, and annually 
thereafter in this event-driven trial until approximately 1,612 primary efficacy endpoint events 
occurred, after which patients made a final end-of-study visit.  
The original projected annual primary endpoint event rate for the REDUCE-IT placebo 
group was 5.9%; this was derived prior to study initiation (and therefore prior to the two interim 
analyses conducted by the data monitoring committee) and was based on data available from 
cardiovascular outcome trials with similar high-risk statin-treated patients and reported endpoint 
components similar to the primary endpoint in REDUCE-IT (23-29). The observed annualized 
primary endpoint event rate for placebo patients in REDUCE-IT was 5.74%, which holds 
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consistent with cardiovascular outcome studies, including those published since the design of 
REDUCE-IT, with comparable patient populations and expanded or hard major adverse 
cardiovascular events (MACE) (4,8,9,30-44). 
For the present pre-specified analysis, the primary outcome was the total of first plus 
subsequent ischemic events consisting of the composite of cardiovascular death, nonfatal 
myocardial infarction, nonfatal stroke, coronary revascularization, or hospitalization for unstable 
angina. Protocol Amendment 2 (July 2016) designated the composite of hard MACE 
(cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke) as the “key secondary 
endpoint” per suggestions from the Food and Drug Administration and with REDUCE-IT 
Steering Committee concordance. Exploratory analyses of the total of first and subsequent events 
were also performed for the key secondary composite endpoint. 
Baseline characteristics were compared between treatment groups using the chi-squared 
test for categorical variables and the Wilcoxon rank sum test for continuous variables. The 
analysis of total cardiovascular events was pre-specified in the study protocol. There are several 
methods for analyzing first and subsequent (recurrent) event data. As a pre-specified statistical 
method, we used the negative binomial regression model to calculate rates and rate ratios for 
total cardiovascular events, which accounts for the variability in each patient’s risk of events (45-
47). As pre-specified supportive analyses, we used the modified Wei-Lin-Weissfeld method (Li 
and Lagakos modification) to calculate hazard ratios for the time to the first event, second event, 
or third event (48-49). An additional pre-specified analysis, the Andersen-Gill model using a 
Cox proportional-hazard with the counting-process formulation was performed to model the total 
events (50,51). In addition, to account for informative censoring due to cardiovascular death, we 
calculated the hazard ratio for total nonfatal events using a joint frailty model (52). The joint 
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frailty model simultaneously estimates hazard functions for nonfatal and fatal cardiovascular 
events and takes into account the fact that patients who are prone to have nonfatal events have an 
elevated risk of a cardiovascular death. Our application of the joint frailty model used a gamma 
distribution for the frailty term. 
To improve the performance and validity of our statistical models, a bundling approach 
was employed, whereby nonfatal events occurring on the same day as a cardiovascular death 
were excluded, and at most, one nonfatal event was counted on any given day (e.g., for coronary 
revascularization occurring after an MI which eventually resulted in the patient’s death, only the 
death would be included). Statistical analyses using the full adjudicated endpoint events dataset 
without exclusions for this bundling approach are also included in the online supplementary 
materials. 
All efficacy analyses were conducted in accordance with the intention-to-treat principle. 
All tests were based on a 2-sided nominal significance level of 5% with no adjustments for 
multiple comparisons, consistent with pre-specified plans for such endpoints. All statistical 
analyses were conducted using SAS version 9.4 software (Cary, North Carolina). All analyses of 
first, subsequent, and total events were independently generated and validated by Drs. Gregson 
and Pocock. 
Results 
A total of 8,179 patients were randomized and followed for a median of 4.9 years. The 
baseline characteristics were well matched across the icosapent ethyl and placebo groups (Online 
Table 1). At baseline, median triglyceride levels were 216 mg/dL, with median LDL-C levels of 
75 mg/dL. Additional baseline characteristics across treatment groups and for patients with no 
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events, a single event, and multiple subsequent events are shown in Online Tables 1 and 2, 
respectively. 
Total events for the primary efficacy endpoint 
Across 8,179 randomized patients, there were 1,606 (55.2%) first primary endpoint 
events and 1,303 (44.8%) additional primary endpoint events, for a total of 2,909 endpoint events 
(Table 1, Online Figures 3, 4, and 5). The proportions of first and subsequent primary endpoint 
events, overall and by component type, are depicted in Figure 1. There were 762 second events, 
272 third events, and 269 fourth or more events. Overall, total (first and subsequent) primary 
endpoint event rates were reduced to 61 from 89 per 1000 patient years for icosapent ethyl versus 
placebo, respectively, rate ratio (RR) 0.70, 95% CI 0.62-0.78, P<0.0001 (Central Illustration, 
Figure 2a). Using the Wei-Lin-Weissfeld model, the first occurrence of a primary composite 
endpoint was reduced with icosapent ethyl versus placebo (HR 0.75, 95% CI 0.68-0.83, P 
<0.0001) as was the second occurrence (hazard ratio [HR] 0.68, 95% CI 0.60-0.78, P <0.0001). 
There was a 30% relative risk reduction in the total (first and subsequent) ischemic events for the 
primary composite endpoint with icosapent ethyl. First events were reduced by 25%, second 
events by 32%, third events by 31%, and fourth or more events by 48%. The cumulative events 
over time are shown in Figure 2. Total key secondary endpoint event rates were significantly 
reduced to 32 from 44 per 1000 patient years for icosapent ethyl versus placebo, respectively 
(RR 0.72, 95% CI 0.63-0.82, P<0.0001) (Figure 2b). The times to first occurrence, second 
occurrence, third occurrence, or fourth occurrence of the primary composite endpoint were 
consistently reduced (Figure 3) with icosapent ethyl. There were similar results for the models 
irrespective of whether bundling and/or single event accounting was employed (Online Tables 3, 
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4, and 5). Total events for each component of the primary endpoint were also significantly 
reduced (Figure 4, Online Figure 3). 
The risk differences for every 1000 patients treated for five years with icosapent ethyl for 
the five components of the composite primary endpoint are shown in Figure 5; approximately 
159 total primary endpoint events could be prevented within that timeframe: 12 cardiovascular 
deaths, 42 myocardial infarctions, 14 strokes, 76 coronary revascularizations, and 16 episodes of 
hospitalization for unstable angina. 
We explored study drug adherence in patients with recurrent events. At the time of a first 
primary endpoint event (fatal or nonfatal), 81.3% (573/705) of icosapent ethyl and 81.8% 
(737/901) of placebo patients with a first primary endpoint event were receiving randomized 
study drug. At the time of subsequent primary endpoint events (fatal or nonfatal), 79.7% 
(188/236) and 79.5% (299/376) of patients with a second event, 68.1% (49/72) and 74.1% 
(106/143) of patients with a third event, and 68.0% (17/25) and 71.6% (48/67) of patients with a 
fourth event were receiving randomized study drug in the icosapent ethyl and placebo groups, 
respectively. Therefore, the majority of the first, second, third, and fourth events occurred while 
patients were on randomized study treatment. Numerical differences in study drug adherence 
among patients with recurrent events were not statistically significant between treatment groups. 
Discussion 
We found large and significant reductions in total ischemic events with icosapent ethyl 
versus placebo in these total event analyses of REDUCE-IT. Three pre-specified and one post 
hoc analyses with various statistical methodologies demonstrated consistent effects on total 
ischemic events, with substantial relative and absolute risk reductions. There was a 30% relative 
risk reduction in the total (first and subsequent) ischemic events for the primary composite 
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endpoint with icosapent ethyl. For every 1,000 patients treated with icosapent ethyl for five 
years, approximately 159 total primary endpoint events could be prevented. Total events for the 
hard MACE key secondary endpoint also demonstrated large and clinically meaningful 
reductions, which further corroborated the significant reduction in important ischemic events 
seen with the primary endpoint. 
There were significant reductions in the first, subsequent, and total ischemic events for 
each individual component of the composite primary endpoint. This benefit of icosapent ethyl 
across a variety of different ischemic endpoints (e.g., coronary, cerebral, fatal and nonfatal 
events, and revascularizations) indicates that the drug benefit is not likely to be explained by 
triglyceride lowering alone and suggests strongly that there are multiple mechanisms of action of 
the drug beyond triglyceride lowering that may work together to achieve the observed benefits. 
Preclinical mechanistic investigations and smaller clinical studies support this contention 
(12,18,19,53-57). 
Icosapent ethyl was well tolerated with no significant differences in rates of serious 
adverse events versus placebo (20). Although overall rates were low in both treatment groups, 
and none of the events were fatal, with icosapent ethyl there was a trend towards increased 
serious bleeding albeit with no significant increases in adjudicated hemorrhagic stroke, serious 
central nervous system bleeding, or gastrointestinal bleeding. There was a small but statistically 
significant increase in hospitalization for atrial fibrillation or flutter endpoints noted in 
REDUCE-IT (20). Nevertheless, the large number of important ischemic events averted with the 
drug, including a significant reduction in fatal and nonfatal stroke (28%), cardiac arrest (48%), 
sudden death (31%), and cardiovascular death (20%), is indicative of a very favorable risk-
benefit profile (20).  
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Study drug adherence in patients with recurrent events was strong in both treatment 
groups at the time of their first primary endpoint event, decreasing somewhat across both 
treatment groups from the occurrence of the first to the fourth event. For example, at the time of 
a first occurrence of a fatal or nonfatal primary endpoint event, 81.3% of icosapent ethyl and 
81.8% of placebo patients with a first primary endpoint event were on study drug; these rates 
decreased to 68.0% and 71.6% for patients with a fourth primary endpoint event.  
The REDUCE-IT primary study results (20) and the recurrent and total endpoint event 
findings discussed herein stand in stark contrast to cardiovascular outcome studies with other 
agents that lower triglyceride levels and with low-dose omega-3 fatty acid mixtures, where 
cardiovascular outcome benefit has not been consistently observed in statin-treated patients (13). 
However, the REDUCE-IT results are aligned with the JELIS study results (17). The distinction 
of the cardiovascular benefits observed in REDUCE-IT and JELIS from the lack of 
cardiovascular benefits observed in statin-treated populations with add-on omega-3 fatty acid 
mixtures is likely due specifically to the high EPA levels. EPA has unique lipid and lipoprotein, 
anti-inflammatory, anti-platelet, anti-thrombotic, and cellular modifying effects, all of which 
may contribute to benefits in atherosclerotic processes such as reduced development, slowed 
progression, and increased stabilization of atherosclerotic plaque (19, 54-56). The aggregate 
contribution of these EPA-related effects may contribute to the large observed reductions in total 
ischemic events with icosapent ethyl. 
The REDUCE-IT patients represent a population at high risk for ischemic events, as 
suggested by the annualized placebo primary endpoint event rate (5.74%), which was expected 
per study design and is consistent with historical data for similar high-risk statin-treated patient 
populations.  It is therefore not surprising that the total atherosclerotic event burden was also 
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high for REDUCE-IT patients.  Substantial and consistent risk reduction with icosapent ethyl 
was observed in the total event analyses for the primary endpoint, for each contributing 
component, and for the key secondary endpoint. Time-to-first-event results provide NNT values 
(21 for the primary endpoint; 28 for the key secondary endpoint); the total event analyses results 
provide incremental evidence of substantial reduction of the total atherosclerotic event burden 
with icosapent ethyl in these patients, with 159 total primary endpoint events prevented for every 
1000 patients treated with icospent ethyl for 5 years.  Given the broad inclusion criteria and 
relatively few exclusion criteria, these results are likely generalizable to a large proportion of at-
risk statin-treated patients with atherosclerosis or diabetes (21). Based on the favorable 
reductions in total ischemic endpoint events, a cost-effectiveness analysis is planned. 
A limitation of this pre-specified analysis is that it is exploratory, and one of the methods 
utilized was post hoc (joint frailty model). Also, total event statistical models can have 
limitations, yet each total event analysis model employed in this manuscript provides 
sophisticated statistical handling of subsequent events, with some distinct and some overlapping 
strengths.  Despite differences in statistical methodologies, the consistency of findings across the 
models speaks to the robustness of the study conclusions and the underlying cardiovascular 
outcomes data. Current analyses of study drug adherence in relation to recurrent events are 
descriptive. In future analyses, we plan to explore further the possible correlations between 
clinical outcomes and study drug adherence, including consideration of possible legacy effects of 
icosapent ethyl. As published previously (20), some biomarkers in the placebo treatment group 
increased from baseline (e.g., median low-density lipoprotein cholesterol was 5 mg/dL higher at 
one year in the placebo group than in the icosapent ethyl group). Such changes are common in 
statin-treated patients within cardiovascular outcome studies (58). Importantly, those biomarker 
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differences had no discernible effect on cardiovascular outcomes in the REDUCE-IT placebo 
group; additionally, the placebo group event rate was as projected during the design phase of 
REDUCE-IT and was also consistent with event rates from other cardiovascular outcome studies 
with similar high-risk statin-treated patients (7,23,25,27). 
In conclusion, icosapent ethyl four grams daily (two grams twice daily) significantly 
reduces total ischemic events in statin-treated patients with well-controlled LDL-C and 
cardiovascular risk factors including elevated triglycerides; benefits were consistently observed 
across a variety of individual ischemic endpoints. In such patients, icosapent ethyl presents an 
important treatment option to further reduce the total burden of atherosclerotic events beyond 
statin therapy alone.  
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Clinical Perspectives 
Competency in Patient Care: Icosapent ethyl 4 grams daily reduces first and subsequent 
cardiovascular events by 30%. Its use should be strongly considered to reduce residual risk in 
patients with elevated triglycerides receiving statin therapy. 
Translational Outlook: Ongoing analyses of multiple biomarkers collected in REDUCE-IT may 
provide additional insight into the biological mechanisms behind the large degree of relative and 
absolute risk reductions with icosapent ethyl seen in a variety of important ischemic events, 
including cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, 
and coronary revascularization. 
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Figure Legends 
Central Illustration. Distribution of First and Subseqent Primary Composite Endpoint 
Events in the Reduced Dataset for Patients Randomized 1:1 to Icosapent Ethyl Versus 
Placebo. Abbreviations: CI = confidence interval; HR = hazard ratio; RR = rate ratio. Hazard 
ratios (HR) and 95% confidence intervals (CI) for between treatment group comparisons were 
generated using Li-Lagakos-modified Wei-Lin-Weissfeld (WLW) method for the 1st event, 2nd 
event, and 3rd event categories. Rate ratio (RR) and 95% CI for between group comparisons 
used a negative binomial model for additional events beyond 1st, 2nd, 3rd occurrences, i.e., 4th 
event or more and overall treatment comparison. Analyses are based on reduced dataset 
accounting for statistical handling of multiple endpoints occurring in a single calendar day by 
counting as a single event. 
Figure 1.  Proportion of First and Subsequent Primary Composite Endpoint Events, 
Overall and by Component. Abbreviations: MI = myocardial infarction. Analyses are based on 
total adjudicated event dataset without accounting for multiple endpoints occuring in a single 
calendar day by counting as a single event. Of the 1,303 subsequent events, 762 were second 
events, 272 third events, and 269 fourth or more events. Primary composite endpoint events: 
cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, coronary revascularization, 
hospitalization for unstable angina. Key secondary composite endpoint events: cardiovascular 
death, nonfatal myocardial infarction, nonfatal stroke. 
Figure 2. Total (First and Subsequent) and Time to First Primary Composite (2A) 
Endpoint Events and Key Secondary Composite (2B) Endpoint Events. Abbreviations: CI = 
confidence interval; HR = hazard ratio; RR = rate ratio.*No. at Risk = Number of patients at risk 
for recurrent events.  The number of patients at risk for the first occurrence of an endpoint event 
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were presented previously in Bhatt DL, Steg PG, Miller M, et al. Cardiovascular risk reduction 
with icosapent ethyl for hypertriglyceridemia. N Engl J Med. 2019;380:11-22. Primary 
composite endpoint events: cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, 
coronary revascularization, and hospitalization for unstable angina. Key secondary composite 
endpoint events: cardiovascular death, nonfatal myocardial infarction, nonfatal stroke.Analyses 
are based on reduced dataset accounting for statistical handling of multiple endpoints occurring 
in a single calendar day by counting as a single event. 
Figure 3. Total Primary and Key Secondary Composite Endpoint Events and First, Second, 
and Third Occurrences. Abbreviations: CI = confidence interval; R = rate ratio. P values from 
Negative Binomial model and Li-Lagakos-modified Wei-Lin-Weissfeld (WLW) models as 
indicated. Analyses are based on reduced dataset accounting for statisical handling of multiple 
endpoints occurring in a single calendar day by counting as a single event. Primary composite 
endpoint events: cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, coronary 
revascularization, hospitalization for unstable angina. Key secondary composite endpoint events: 
cardiovascular death, nonfatal myocardial infarction, nonfatal stroke. For the modified WLW 
analysis, second event is defined as nonfatal second event or cardiovascular death, and third 
event is defined as nonfatal third event or cardiovascular death. Due to the low number of fourth 
or more events, only first, second, and third events are displayed (please see Online Figure 3). 
Figure 4. Total Primary and Key Secondary Composite Endpoints and Each Individual 
Component or Other Composite Endpoints. Abbreviations: CI = confidence interval; HR, 
hazard ratio; P values from Negative Binomial model. Primary composite endpoint events: 
cardiovascular death. nonfatal myocardial infarction, nonfatal stroke, coronary revascularization, 
hospitalization for unstable angina. Key secondary composite endpoint events: cardiovascular 
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death, nonfatal myocardial infarction, nonfatal stroke. Analyses are based on reduced dataset 
accounting for statistical handling of multiple endpoints occurring in a single calendar day by 
counting as a single event. 
Figure 5. Risk Differences for 1000 Patients Treated For 5 Years with Icosapent Ethyl 
Versus Placebo for the Total Components of the Composite Primary Endpoint. 
Abbreviations: MI = myocardial infarction. Analyses are based on total adjudicated event dataset 
without accounting for multiple endpoints occurring in a single calendar day by counting as a 
single event. 
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Table 1: Total Primary and Key Secondary Composite Endpoint Accounting for Statistical Handling of Multiple Endpoints 
Occuring in a Single Calendar Day as a Single Event 
 
n (%) 
Primary composite endpoint Key secondary composite endpoint 
Icosapent ethyl 
(N=4089) 
Placebo 
(N=4090) 
Overall 
(N=8179) 
Icosapent ethyl 
(N=4089) 
Placebo 
(N=4090) 
Overall 
(N=8179) 
Total events before 
reduction 1185 (40.7) 1724 (59.3) 2909* (100) 590 (42.0) 816 (58.0) 1406 (100) 
       
Total events after 
reductionɫ 1076 (41.0) 1546 (59.0) 2622 (100) 558 (42.1) 767 (57.9) 1325 (100) 
    Fatal events 174 (45.0) 213 (55.0) 387 (100) 174 (45.0) 213 (55.0) 387 (100) 
    Nonfatal events 902 (40.4) 1333 (59.6) 2235 (100) 384 (40.9) 554 (59.1) 938 (100) 
Percentages are based on the total number of randomized patients within each category. 
Note: See also Online Figures 3 and 4 
Primary composite endpoint events: cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, coronary revascularization, 
hospitalization for unstable angina  
Key secondary composite endpoint events: cardiovascular death, nonfatal myocardial infarction, nonfatal stroke. 
* A single event was experienced by 844 patients (844 events) and 2 or more events were experienced by 762 patients (2,065) events, 
for a total of 1,606 patients experiencing a total of 2,909 events.  
ɫ Reduction means 1) any nonfatal events on the same day as death are removed and 2) if 2 nonfatal events occur on the same day only 
the first one is counted.  
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Online Appendix for Recurrent Events Manuscript for JACC DLB 02 24 2019 
1 
CONFIDENTIAL 
Online Appendix 
Online Table 1. Baseline Characteristics of Patients in Icosapent Ethyl and Placebo Treatment Groups 
 
 
Icosapent Ethyl                                                                                                              
(N=4089) 
Placebo
(N=4090) P Value 
[1]
 
Demographics 
Age (years), Median (Q1-Q3) 64.0 (57.0 - 69.0) 64.0 (57.0 - 69.0) 0.7446 
Age ≥65 years, n (%) 1857 (45.4%) 1906 (46.6%) 0.2815 
Male, n (%) 2927 (71.6%) 2895 (70.8%) 0.4245 
White, n (%)
[2]
 3691 (90.3%) 3688 (90.2%) 0.9110 
BMI (kg/m
2
), Median (Q1-Q3) 30.8 (27.8 - 34.5) 30.8 (27.9 - 34.7) 0.3247 
BMI ≥30, n (%)
[3]
 2331 (57.0%) 2362 (57.8%) 0.5287 
Stratification Factors       
Geographic Region, n (%)   0.9924 
   Westernized 
[4]
 2906 (71.1%) 2905 (71.0%)        
   Eastern Europe 
[5]
 1053 (25.8%) 1053 (25.7%)        
   Asia Pacific 
[6]
  130 (3.2%)  132 (3.2%)        
CV Risk Category, n (%)   0.9943 
   Secondary Prevention  2892 (70.7%) 2893 (70.7%)        
   Primary Prevention  1197 (29.3%) 1197 (29.3%)        
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Icosapent Ethyl                                                                                                              
(N=4089) 
Placebo
(N=4090) P Value 
[1]
 
Ezetimibe Use, n (%)  262 (6.4%)  262 (6.4%) 0.9977 
Statin Intensity and Diabetes Status 
Statin Intensity, n (%)   0.1551 
   Low  254 (6.2%)  267 (6.5%)        
   Moderate 2533 (61.9%) 2575 (63.0%)        
   High 1290 (31.5%) 1226 (30.0%)        
   Missing   12 (0.3%)   22 (0.5%)        
Diabetes, n (%)   0.9926 
   Type 1 Diabetes   27 (0.7%)   30 (0.7%)        
   Type 2 Diabetes 2367 (57.9%) 2363 (57.8%)        
   No Diabetes at Baseline 1695 (41.5%) 1694 (41.4%)        
   Missing 0 3 (0.1%)  
Laboratory Measurements       
hsCRP (mg/L), Median (Q1-Q3) 2.2 (1.1 - 4.5) 2.1 (1.1 - 4.5) 0.7197 
Triglycerides (mg/dL), Median (Q1-Q3) 216.5 (176.5 - 272.0) 216.0 (175.5 - 274.0) 0.9120 
Triglycerides Category, n (%)   0.8297 
   <150 mg/dL 412 (10.1%) 429 (10.5%)  
   150 to < 200 mg/dL 1193 (29.2%) 1191 (29.1%)        
   ≥ 200 mg/dL 2481 (60.7%) 2469 (60.4%)        
Triglycerides Tertiles, n (%)   0.4887 
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Icosapent Ethyl                                                                                                              
(N=4089) 
Placebo
(N=4090) P Value 
[1]
 
   Lowest (≤190 mg/dL) 1378 (33.7%) 1381 (33.8%)  
   Middle (>190 – ≤250 mg/dL) 1370 (33.5%) 1326 (32.4%)  
   Upper (>250 mg/dL) 1338 (32.7%) 1382 (33.8%)  
   Missing 3 (0.1%) 1   
Triglycerides ≥ 200 mg/dL and HDL-C ≤ 35 mg/dL, n (%)  823 (20.1%)  794 (19.4%) 0.4019 
HDL-C (mg/dL), Median (Q1-Q3) 40.0 (34.5 - 46.0) 40.0 (35.0 - 46.0) 0.1370 
LDL-C (mg/dL), Median (Q1-Q3) 74.0 (61.5 - 88.0) 76.0 (63.0 - 89.0) 0.0284 
LDL-C Tertiles, n (%)   0.0556 
   Lowest (≤67 mg/dL) 1481 (36.2%) 1386 (33.9%)  
   Middle (>67 – ≤84 mg/dL) 1347 (32.9%) 1364 (33.3%)  
   Upper (>84 mg/dL) 1258 (30.8%) 1339 (32.7%)  
   Missing 3 (0.1%) 1   
EPA (μg/mL), Median (Q1-Q3) 26.1 (17.1 - 40.1) 26.1 (17.1 - 39.9) 0.8867 
Cardiovascular Disease History
[7]
 
Prior Atherosclerotic Cardiovascular Disease (ASCVD), n (%) 2816 (68.9%) 2835 (69.3%)  0.6667 
   Prior Atherosclerotic Coronary Artery Disease and Related Morbidities 2387 (58.4%) 2393 (58.5%)  0.9107 
   Ischemic Dilated Cardiomyopathy 137 (3.4%) 109 (2.7%) 0.0702 
   Myocardial Infarction  1938 (47.4%) 1881 (46.0%) 0.2065 
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Icosapent Ethyl                                                                                                              
(N=4089) 
Placebo
(N=4090) P Value 
[1]
 
   Unstable Angina 1017 (24.9%) 1015 (24.8%) 0.9592 
Prior Atherosclerotic Cerebrovascular Disease and Related Morbidities, n (%) 641 (15.7%) 662 (16.2%) 0.5457 
   Carotid Disease  343 (8.4%) 372 (9.1%)   0.2730 
   Ischemic Stroke  267 (6.5%) 242 (5.9%)  0.2529 
   Transient Ischemic Attack  194 (4.7%) 181 (4.4%)   0.4925 
Prior Atherosclerotic Peripheral Arterial Disease, n (%) 387 (9.5%) 388 (9.5%) 1.0000 
   ABI <0.9 Without Symptoms of Intermittent Claudication  97 (2.4%) 76 (1.9%) 0.1073 
   Peripheral Artery Disease 377 (9.2%) 377 (9.2%) 1.0000 
Prior Non-Atherosclerotic Cardiovascular Disease, n (%) 3649 (89.2%) 3645 (89.1%)   0.8868 
   Prior Structural Cardiac Disorders  827 (20.2%) 866 (21.2%)   0.2997 
      Heart Failure  703 (17.2%) 743 (18.2%)   0.2583 
      Hypertrophic Cardiomyopathy  23 (0.6%) 20 (0.5%)   0.6507 
      Non-Ischemic Dilated Cardiomyopathy  35 (0.9%) 29 (0.7%)   0.4552 
      Non-Rheumatic Valvular Heart Disease  150 (3.7%) 163 (4.0%)   0.4892 
     Rheumatic Valvular Heart Disease  17 (0.4%) 9 (0.2%)   0.1215 
   Prior Cardiac Arrhythmias 229 (5.6%) 243 (5.9%)  0.5377 
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Icosapent Ethyl                                                                                                              
(N=4089) 
Placebo
(N=4090) P Value 
[1]
 
      Atrio-Ventricular Block Above First Degree 51 (1.2%) 54 (1.3%)  0.8444 
      Sick Sinus Syndrome 30 (0.7%) 32 (0.8%)  0.8987 
      Supra-Ventricular Tachycardia Other Than Atrial Fibrillation /Atrial flutter 74 (1.8%) 77 (1.9%)  0.8696 
      Sustained Ventricular Tachycardia 34 (0.8%) 34 (0.8%)  1.0000 
      Torsades De Pointes 1 (0.0%) 3 (0.1%)  0.6249 
      Ventricular Fibrillation    61 (1.5%) 65 (1.6%) 0.7877 
Prior Non-Cardiac/Non-Atherosclerotic Vascular Disorders, n (%) 3568 (87.3%) 3566 (87.2%) 0.9472 
   Arterial Embolism  12 (0.3%) 9 (0.2%)   0.5229 
   Deep Vein Thrombosis  70 (1.7%) 60 (1.5%)   0.3785 
   Hypertension  3541 (86.6%) 3543 (86.6%) 0.9741 
   Hypotension 45 (1.1%) 33 (0.8%) 0.1745 
   Pulmonary Embolism  31 (0.8%) 42 (1.0%) 0.2396 
   Non-Ischemic Stroke 79 (1.9%) 84 (2.1%) 0.7518 
      Hemorrhagic Stroke  18 (0.4%) 22 (0.5%)   0.6350 
      Stroke of Unknown Origin  63 (1.5%) 62 (1.5%)   0.9285 
Other Prior Conditions or Investigations Influencing Cardiovascular Risk 
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Icosapent Ethyl                                                                                                              
(N=4089) 
Placebo
(N=4090) P Value 
[1]
 
BaselineLaboratory Abnormalities, n (%) 1783 (43.6%) 1707 (41.7%) 0.0893 
   Renal Disorders 470 (11.5%) 429 (10.5%) 0.1474 
      Creatinine Clearance (CRCL) >30 and <60 ML/Min 309 (7.6%) 286 (7.0%) 0.3279 
      Macroalbuminuria  34 (0.8%) 24 (0.6%)   0.1909 
      Microalbuminuria 146 (3.6%) 134 (3.3%)   0.4664 
      Proteinuria  75 (1.8%) 63 (1.5%) 0.3046 
Other Morbidities 173 (4.2%) 173 (4.2%) 1.0000 
   Pancreatitis 14 (0.3%) 9 (0.2%)  0.3067 
   Retinopathy 161 (3.9%) 167 (4.1%)  0.7782 
Carotid Stenosis 
[8]
      
    n 316 346  
   Mean (%) (SD) 59.0 (21.04) 56.9 (22.99) 0.4101 
Medication Taken at Baseline 
Anti-Diabetic, n (%) 2190 (53.6%) 2196 (53.7%)  0.9036 
Anti-Hypertensive 3895 (95.3%) 3895 (95.2%)  0.9605 
Anti-Platelet
[9]
 3257 (79.7%) 3236 (79.1%) 0.5514 
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Icosapent Ethyl                                                                                                              
(N=4089) 
Placebo
(N=4090) P Value 
[1]
 
  One Anti-platelet 2416 (59.09%) 2408 (58.88%) 0.8469 
  Two or more Anti-platelets  841 (20.57%)  828 (20.24%) 0.7171 
Anticoagulant 385 (9.4%) 390 (9.5%)  0.8531 
Anticoagulant plus Anti-platelet 137 (3.4%) 137 (3.4%)  0.9984 
No Antithrombotic 584 (14.3%) 601 (14.7%)  0.5965 
ACE 2112 (51.7%) 2131 (52.1%)  0.6825 
ARB 1108 (27.1%) 1096 (26.8%)  0.7598 
ACE or ARB 3164 (77.4%) 3176 (77.7%)  0.7662 
Beta Blockers 2902 (71.0%) 2880 (70.4%)  0.5812 
Abbreviations: ABI = ankle brachial index; ACE = angiotensin-converting enzyme; ARB = angiotensin receptor blockers. 
 
In general, the baseline value is defined as the last non-missing measurement obtained prior to the randomization. 
The baseline LDL-C value obtained via Preparative Ultracentrifugation was used, unless this value was missing. If the LDL-C Preparative 
Ultracentrifugation value was missing, then another LDL-C value was be used, with prioritization of values obtained from LDL-C Direct 
measurements, followed by LDL-C derived by the Friedewald calculation (only for subjects with TG < 400 mg/dL), and finally LDL-C derived 
using the calculation published by Johns Hopkins University investigators (1). 
For all other lipid and lipoprotein marker parameters, wherever possible, baseline was derived as the arithmetic mean of the Visit 2 (Day 0) value 
and the preceding Visit 1 (or Visit 1.1) value. If only one of these values was available, the single available value was used as baseline. 
 
[1] P-value comparing two treatment groups is from a Wilcoxon test for continuous variables and a Chi-Square test for categorical variables. 
[2] Race as reported by the investigators. 
[3] Body-mass index is the weight in kilograms divided by the square of the height in meters. 
[4] Westernized region includes Australia, Canada, Netherlands, New Zealand, United States, and South Africa. 
[5] Eastern European region includes Poland, Romania, Russian Federation, and Ukraine. 
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[6] Asia Pacific region includes India. 
[7] The summary is based on the data collected from CV history Case Report Form (CRF). 
[8] Two outliers of Carotid Stenosis (%) with a value over 100% are excluded from the analysis.  Carotid Stenosis (%) data reported in categorical 
format of >x% and <y% is analysed as x% and y%, respectively; and data reported as x% to y% is analysed as an average of x% and y%. 
[9] Anti-platelet medications were classified as dual if both components have a regulatory approval affirming anti-platelet effects. Combinations 
where one element lacks such regulatory approval were excluded (e.g. aspirin + magnesium oxide is classified as a single agent because the latter 
component is not approved as an anti-platelet agent).
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Online Appendix for Recurrent Events Manuscript for JACC DLB 02 24 2019 
9 
CONFIDENTIAL 
 
Online Table 2. Baseline Characteristics of Patients with No Primary Endpoint Events, a Single Event, or Multiple Events  
 No Events  
(N=6573) 
1 Event  
(N=844) 
Multiple Events 
(N=762) 
P Value 
[1]
 
Demographics 
Age (years), Median (Q1-Q3) 63.0 (57.0 - 69.0) 65.0 (59.0 - 71.0) 64.0 (58.0 - 70.0) 0.0400 
Age ≥ 65 years, n (%) 2939 (44.7%)  456 (54.0%)  368 (48.3%) 0.0217 
Male, n (%) 4556 (69.3%)  661 (78.3%)  605 (79.4%) 0.5972 
White, n (%)
[2]
 5921 (90.1%)  765 (90.6%)  693 (90.9%) 0.8328 
BMI (kg/m
2
), Median (Q1-Q3) 30.8 (27.8 - 34.6) 31.1 (27.8 - 34.7) 30.8 (28.0 - 34.2) 0.2609 
BMI ≥ 30, n (%)
[3]
 3762 (57.2%)  499 (59.1%)  432 (56.7%) 0.4656 
Stratification Factors       
Geographic Region    0.0082 
   Westernized 
[4]
 4547 (69.2%)  639 (75.7%)  625 (82.0%)        
   Eastern Europe 
[5]
 1796 (27.3%)  185 (21.9%)  125 (16.4%)        
   Asia Pacific [6]  230 (3.5%)   20 (2.4%)   12 (1.6%)        
CV Risk Category as Randomized, n (%)    <.0001 
   Secondary Prevention  4488 (68.3%)  640 (75.8%)  657 (86.2%)        
   Primary Prevention  2085 (31.7%)  204 (24.2%)  105 (13.8%)        
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 No Events  
(N=6573) 
1 Event  
(N=844) 
Multiple Events 
(N=762) 
P Value 
[1]
 
Ezetimibe Use, n (%)  401 (6.1%)   59 (7.0%)   64 (8.4%) 0.2892 
Statin Intensity and Diabetes Status 
Statin Intensity, n (%)    0.7138 
   Low  428 (6.5%)   49 (5.8%)   44 (5.8%)        
   Moderate 4141 (63.0%)  519 (61.5%)  448 (58.8%)        
   High 1974 (30.0%)  274 (32.5%)  268 (35.2%)        
   Missing   30 (0.5%)    2 (0.2%)    2 (0.3%)        
Diabetes, n (%)    0.4420 
   Type 1 Diabetes   44 (0.7%)    5 (0.6%)    8 (1.0%)        
   Type 2 Diabetes 3774 (57.4%)  511 (60.5%)  445 (58.4%)        
   No Diabetes at Baseline 2752 (41.9%)  328 (38.9%)  309 (40.6%)        
   Missing    3 (0.0%)    0    0        
Laboratory Measurements             
hsCRP (mg/L), Median (Q1-Q3) 2.1 (1.1 - 4.4) 2.4 (1.2 - 5.3) 2.4 (1.2 - 4.6) 0.3325 
Triglycerides (mg/dL), Median (Q1-Q3) 215.5 (176.0 - 
272.0) 
215.5 (175.0 - 
270.3) 
223.0 (178.5 - 285.5) 0.0701 
Triglycerides Category    0.2017 
   < 150 mg/dL 686 (10.4%)  79 (9.4%)  76 (10.0%)  
   150 to <200 mg/dL 1922 (29.2%)  259 (30.7%)  203 (26.6%)        
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 No Events  
(N=6573) 
1 Event  
(N=844) 
Multiple Events 
(N=762) 
P Value 
[1]
 
   ≥ 200 mg/dL 3961 (60.3%)  506 (60.0%)  483 (63.4%)        
Triglycerides Tertiles, n (%)    0.1993 
    Lowest (≤190 mg/dL) 2235 (34.0%) 287 (34.0%) 237 (31.1%)  
    Middle (>190 – ≤250 mg/dL) 2167 (33.0%) 283 (33.5%) 246 (32.3%)  
    Upper (>250 mg/dL) 2167 (33.0%) 274 (32.5%) 279 (36.6%)  
Triglycerides ≥ 200 mg/dL and HDL-C ≤ 35 mg/dL 1254 (19.1%)  173 (20.5%)  190 (24.9%) 0.0336 
HDL-C (mg/dL), Median (Q1-Q3) 40.0 (35.0 - 46.0) 39.5 (34.4 - 45.5) 38.8 (33.5 - 44.5) 0.0631 
LDL-C (mg/dL), Median (Q1-Q3) 75.0 (62.0 - 89.0) 75.0 (63.0 - 88.0) 75.0 (63.0 - 89.0) 0.7384 
LDL-C Tertiles, n (%)    0.5416 
    Lowest (≤67 mg/dL) 2321 (35.3%) 283 (33.5%) 263 (34.5%)  
    Middle (>67 – ≤84 mg/dL) 2156 (32.8%) 302 (35.8%) 253 (33.2%)  
    Upper (>84 mg/dL) 2092 (31.8%) 259 (30.7%) 246 (32.3%)  
EPA (μg/mL), Median (Q1-Q3) 26.2 (17.2 - 40.4) 24.6 (15.9 - 36.7) 26.9 (17.7 - 40.2) 0.0120 
Cardiovascular Disease History [7] 
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 No Events  
(N=6573) 
1 Event  
(N=844) 
Multiple Events 
(N=762) 
P Value 
[1]
 
Prior Atherosclerotic Cardiovascular Disease (ASCVD) 4370 (66.5%) 633 (75.0%) 648 (85.0%) <0.0001 
   Prior Atherosclerotic Coronary Artery Disease and Related Morbidities 3662 (55.7%) 542 (64.2%) 576 (75.6%) <0.0001 
      Myocardial Infarction 2931 (44.6%) 430 (50.9%) 458 (60.1%) 0.0002 
      Unstable Angina 1497 (22.8%) 236 (28.0%) 299 (39.2%) <0.0001 
      Ischemic Dilated Cardiomyopathy 164 (2.5%) 46 (5.5%) 36 (4.7%)   0.5707 
   Prior Atherosclerotic Cerebrovascular Disease and Related Morbidities 965 (14.7%) 173 (20.5%) 165 (21.7%)   0.5816 
      Carotid Disease 543 (8.3%) 90 (10.7%) 82 (10.8%) 1.0000 
      Ischemic Stroke 380 (5.8%) 64 (7.6%) 65 (8.5%)   0.5203 
      Transient Ischemic Attack 254 (3.9%) 61 (7.2%) 60 (7.9%) 0.6371 
   Prior Atherosclerotic Peripheral Arterial Disease 548 (8.3%) 109 (12.9%) 118 (15.5%)  0.115 
      Peripheral Artery Disease 534 (8.1%) 106 (12.6%) 114 (15.0%)  0.1679 
      ABI <0.9 Without Symptoms of Intermittent Claudication 132 (2.0%) 24 (2.8%) 17 (2.2%)  0.5269 
Prior Non-Atherosclerotic Cardiovascular Disease 5836 (88.8%) 775 (91.8%) 683 (89.6%)  0.1420 
   Prior Structural Cardiac Disorders 1289 (19.6%) 234 (27.7%) 170 (22.3%)  0.0133 
      Heart Failure 1099 (16.7%) 200 (23.7%) 147 (19.3%)  0.0337 
      Hypertrophic Cardiomyopathy 32 (0.5%) 6 (0.7%) 5 (0.7%)  1.0000 
      Non-Ischemic Dilated Cardiomyopathy 49 (0.7%) 11 (1.3%) 4 (0.5%)  0.1239 
      Non-Rheumatic Valvular Heart Disease 225 (3.4%) 54 (6.4%) 34 (4.5%)  0.0996 
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 No Events  
(N=6573) 
1 Event  
(N=844) 
Multiple Events 
(N=762) 
P Value 
[1]
 
      Rheumatic Valvular Heart Disease 22 (0.3%) 3 (0.4%) 1 (0.1%)  0.6265 
   Prior Cardiac Arrhythmias 354 (5.4%) 65 (7.7%) 53 (7.0%)  0.6322 
      Atrio-Ventricular Block Above First Degree 77 (1.2%) 15 (1.8%) 13 (1.7%)  1.0000 
      Sick Sinus Syndrome 49 (0.7%) 5 (0.6%) 8 (1.0%)  0.4056 
      Supra-Ventricular Tachycardia Other Than Atrial fibrillation/Atrial     
flutter 
115 (1.7%) 24 (2.8%) 12 (1.6%)  0.0934 
      Sustained Ventricular Tachycardia 50 (0.8%) 10 (1.2%) 8 (1.0%)  0.8179 
      Torsades De Pointes 3 (0.0%) 0 (0.0%) 1 (0.1%)  0.4745 
      Ventricular Fibrillation 95 (1.4%) 16 (1.9%) 15 (2.0%) 1.0000 
   Prior Non-Cardiac/Non-Atherosclerotic Vascular Disorders 5716 (87.0%) 752 (89.1%) 666 (87.4%)  0.3125 
      Hypotension 52 (0.8%) 9 (1.1%) 17 (2.2%)  0.0754 
      Hypertension 5669 (86.2%) 750 (88.9%) 665 (87.3%)  0.3544 
      Non-Ischemic Stroke 123 (1.9%) 24 (2.8%) 16 (2.1%)  0.4231 
         Hemorrhagic Stroke 32 (0.5%) 4 (0.5%) 4 (0.5%)  1.0000 
         Stroke of Unknown Origin 92 (1.4%) 20 (2.4%) 13 (1.7%)  0.3826 
      Arterial Embolism 9 (0.1%) 11 (1.3%) 1 (0.1%)  0.0069 
      Deep Vein Thrombosis 90 (1.4%) 20 (2.4%) 20 (2.6%)  0.7514 
      Pulmonary Embolism 49 (0.7%) 12 (1.4%) 12 (1.6%)  0.8391 
Other Prior Conditions or Investigations Influencing Cardiovascular Risk 4870 (74.1%) 642 (76.1%) 587 (77.0%)  0.6799 
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 No Events  
(N=6573) 
1 Event  
(N=844) 
Multiple Events 
(N=762) 
P Value 
[1]
 
   Prior Metabolic Disorders 3988 (60.7%) 530 (62.8%) 477 (62.6%)  0.9588 
      Type 1 Diabetes 45 (0.7%) 5 (0.6%) 8 (1.0%)  0.4056 
      Type 2 Diabetes 3774 (57.4%) 511 (60.5%) 445 (58.4%)  0.3872 
   Baseline Laboratory Abnormalities 2725 (41.5%) 395 (46.8%) 370 (48.6%)  0.4842 
      Renal Disorders 660 (10.0%) 129 (15.3%) 110 (14.4%)  0.6737 
         Creatinine Clearance >30 And <60 mL/Min 430 (6.5%) 83 (9.8%) 82 (10.8%)  0.5651 
         Proteinuria 100 (1.5%) 20 (2.4%) 18 (2.4%)  1.0000 
         Macroalbuminuria 43 (0.7%) 7 (0.8%) 8 (1.0%)  0.7964 
         Microalbuminuria 217 (3.3%) 38 (4.5%) 25 (3.3%)  0.2468 
   Other Morbidities 275 (4.2%) 42 (5.0%) 29 (3.8%)  0.2754 
      Pancreatitis 19 (0.3%) 2 (0.2%) 2 (0.3%)  1.0000 
      Retinopathy 259 (3.9%) 42 (5.0%) 27 (3.5%)  0.1758 
Carotid Stenosis
[8]
       
   n 503 86 73  
   Mean (%) (SD) 57.0(21.94) 58.2(22.85) 63.5(21.67) 0.1582 
Medication Taken at Baseline 
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 No Events  
(N=6573) 
1 Event  
(N=844) 
Multiple Events 
(N=762) 
P Value 
[1]
 
Anti-Diabetic 3498 (53.2%)  478 (56.6%)  410 (53.8%)  0.2548 
Anti-Hypertensive 6239 (94.9%)  817 (96.8%)  734 (96.3%)  0.6008 
Anti-Platelet 5138 (78.2%)  691 (81.9%)  664 (87.1%)  0.0037 
  One Anti-platelet 3912 (59.52%)  486 (57.58%)  426 (55.91%) 0.4980 
  Two or more Anti-platelets 1226 (18.65%)  205 (24.29%)  238 (31.23%) 0.0019 
Anticoagulant  560 (8.5%)  125 (14.8%)   90 (11.8%)  0.0780 
Anticoagulant plus Anti-platelet  185 (2.8%)   46 (5.5%)   43 (5.6%)  0.8661 
No Antithrombotic 1060 (16.1%)   74 (8.8%)   51 (6.7%)  0.1212 
ACE 3424 (52.1%)  429 (50.8%)  390 (51.2%)  0.8880 
ARB 1743 (26.5%)  235 (27.8%)  226 (29.7%)  0.4220 
ACE or ARB 5090 (77.4%)  645 (76.4%)  605 (79.4%)  0.1518 
Beta Blockers 4541 (69.1%)  655 (77.6%)  586 (76.9%)  0.7368 
 
Abbreviations: ABI = ankle brachial index; ACE = angiotensin-converting enzyme; ARB = angiotensin receptor blockers. 
 
In general, the baseline value is defined as the last non-missing measurement obtained prior to the randomization. 
The baseline LDL-C value obtained via Preparative Ultracentrifugation was used, unless this value was missing. If the LDL-C 
Preparative Ultracentrifugation value was missing, then another LDL-C value was be used, with prioritization of values obtained from 
LDL-C Direct measurements, followed by LDL-C derived by the Friedewald calculation (only for subjects with TG < 400 mg/dL), 
and finally LDL-C derived using the calculation published by Johns Hopkins University investigators (1). 
For all other lipid and lipoprotein marker parameters, wherever possible, baseline was derived as the arithmetic mean of the Visit 2 
(Day 0) value and the preceding Visit 1 (or Visit 1.1) value. If only one of these values was available, the single available value was 
used as baseline. 
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[1] P-value comparing Single Event group with Multiple Events group is from a Wilcoxon test for continuous variables and a Chi-
Square test for categorical variables. 
[2] Race as reported by the investigators. 
[3] Body-mass index is the weight in kilograms divided by the square of the height in meters. 
[4] Westernized region includes Australia, Canada, Netherlands, New Zealand, United States, and South Africa. 
[5] Eastern European region includes Poland, Romania, Russian Federation, and Ukraine. 
[6] Asia Pacific region includes India. 
[7] The summary is based on the data collected from CV history Case Report Form (CRF). 
[8] Two outliers of Carotid Stenosis (%) with a value over 100% are excluded from the analysis.  Carotid Stenosis (%) data reported in 
categorical format of >x% and <y% is analysed as x% and y%, respectively; and data reported as x% to y% is analysed as an average 
of x% and y%. 
[9] Anti-platelet medications were classified as dual if both components have a regulatory approval affirming anti-platelet effects. 
Combinations where one element lacks such regulatory approval were excluded (e.g. aspirin + magnesium oxide is classified as a 
single agent because the latter component is not approved as an anti-platelet agent).
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Online Table 3. Hazard Ratios for Pre-Specified Analyses of Total for Primary and Key Secondary Composite Endpoint 
Events Using the Reduced Dataset 
 
  Primary composite endpoint Key secondary composite endpoint 
 
 Unadjusted 
RR/HR 
(95% CI) 
Unadjusted 
p-value 
Adjusted RR/HR 
(95% CI) 
Adjusted p-
value 
Unadjusted RR/HR 
(95% CI) 
Unadjusted 
p-value 
Adjusted RR/HR (95% 
CI) 
Adjusted 
p-value 
Negative 
binomial 
 
0.68 
(0.61, 0.77) 
1.5 x 10
-10
 
0.70 
(0.62, 0.78) 
3.6 x 10
-10
 
0.71 
(0.62, 0.82) 
8.9 x 10
-7
 
0.72 
(0.63, 0.82) 
7.1 x 10
-7
 
Andersen-Gill 
(I) 
 
0.69 
(0.64, 0.74) 
3.5 x 10
-21
 
0.69 
(0.64, 0.74) 
3.3 x 10
-21
 
0.72 
(0.64, 0.80) 
2.4 x 10
-9
 
0.72 
(0.64, 0.80) 
2.4 x 10
-9
 
Andersen-Gill 
(II)  
0.69 
(0.61, 0.77) 
9.1 x 10
-11
 
0.69 
(0.61, 0.77) 
5.2 x 10
-11
 
0.72 
(0.63, 0.82) 
1.2 x10
-6
 
0.72 
(0.63, 0.82) 
1.0 x 10
-6
 
Modified WLW First event 
0.76 
(0.69, 0.83) 
2.7 x 10
-8
 
0.75 
(0.68, 0.83) 
1.6 x 10
-8
 
0.74 
(0.65, 0.83) 
7.4 x 10
-7
 
0.74 
(0.65, 0.83) 
7.0 x 10
-7
 
 
Second 
event 
0.69 
(0.60, 0.79) 
2.7 x 10-8 
0.68 
(0.60, 0.78) 
1.8 x 10-8 
0.75 
(0.63, 0.89) 
1.1 x 10-3 
0.75 
(0.63, 0.89) 
1.1 x 10-3 
 Third event 
0.69 
(0.59, 0.82) 
2.1 x 10
-5
 
0.69 
(0.59, 0.82) 
2.0 x 10
-5
 
0.79 
(0.65, 0.96) 
.0170 
0.79 
(0.65, 0.96) 
.0171 
 
Abbreviations: CI = confidence interval; HR = hazard ratio; RR = rate ratio; WLW = Wei-Lin-Weisfeld. 
Rate ratios (RR) are presented for results from negative binomial model; Hazard ratios (HR) are presented for results from Andersen 
Gill (I) model, Andersen Gill (II) model, and modified Wei-Lin-Weisfeld model. 
Unadjusted analyses only included treatment group in the model; Adjusted analyses also included stratification factors (cardiovascular 
risk category, geographic region, and use of ezetimibe) as covariate, in addition to treatment group in the model. 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Online Appendix for Recurrent Events Manuscript for JACC DLB 02 24 2019 
18 
CONFIDENTIAL 
Negative binomial model (2-4). 
Andersen Gill (I) model is based on an intensity model with model-based variance estimate and was a pre-specified methodology (5).  
Andersen Gill (II) model is based on a proportional means model with cluster-robust standard errors, with the cluster set to the patient 
ID. This is an updated methodology (6).  
Wei-Lin-Weisfeld model is based on Li-Lagakos modification (7,8).  In this modified WLW analysis, second event is defined as 
nonfatal second event or cardiovascular death, and third event is defined as nonfatal third event or cardiovascular death. 
Analyses are based on reduced dataset accounting for statistical handling of multiple endpoints occurring in a single calendar day as a 
single event. 
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Online Table 4. Results from Joint Frailty Model for Primary and Key Secondary Composite Endpoints Using the Reduced 
Dataset 
  
Nonfatal Cardiovascular Event Cardiovascular Death 
  
HR 
(95% CI) 
P-value 
HR 
(95% CI) 
P-value 
Primary composite endpoint 
Unadjusted 
0.66 
(0.60, 0.73) 
7.40 x 10-17 
0.80 
(0.65, 0.98) 
0.0282 
Adjusted 
0.67 
(0.61, 0.74) 
7.20 x 10
-16
 
0.80 
(0.65, 0.98) 
0.0306 
Key secondary composite 
endpoint 
Unadjusted 
0.68 
(0.59, 0.78) 
3.30 x 10
-8
 
0.79 
(0.63, 0.99) 
0.0366 
Adjusted 
0.68 
(0.59, 0.78) 
4.30 x 10
-8
 
0.79 
(0.63, 0.99) 
0.0380 
 
Abbreviations: CI, confidence interval; HR, hazard ratio. 
 
Joint frailty model is based on Rondeau (2007) implemented in the frailtypack R package (9). Default settings were used, except that 3 
knots were used to model the baseline hazard function (to improve speed given that we know from the mean cumulative plots that the 
shape of the baseline hazard function is unlikely to be complex) and recurrentAG==TRUE (i.e., thereby assuming independence 
between events conditional on the frailty term). 
 
Unadjusted analyses only included treatment group in the model; Adjusted analyses also included stratification factors (cardiovascular 
risk category, geographic region, and use of ezetimibe) as covariate, in addition to treatment group in the model. 
 
Analyses are based on reduced dataset accounting for statistical handling of multiple endpoints occurring in a single calendar day as a 
single event. 
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Online Table 5. Hazard and Rate Ratios for Pre-Specified Analyses for Primary and Key Secondary Composite Endpoints 
Using the Full Dataset 
 
 
Primary Composite Endpoint Key Secondary Composite Endpoint  
Unadjusted Adjusted Unadjusted Adjusted 
RR/HR  
(95% CI) 
p-value 
RR/HR  
(95% CI) 
p-value 
RR/HR  
(95% CI) 
p-value 
HR  
(95% CI) 
p-value 
Negative binomial 
0.67  
(0.60, 0.76) 
1.6 x 10
-10
 
0.69  
(0.61, 0.77) 
4.4 x 10
-10
 
0.71  
(0.62, 0.81) 
1.4 x 10
-6
 
0.71  
(0.62, 0.82) 
1.2 x 10
-6
 
Andersen-Gill (I) 0.68  
(0.63, 0.74) 
3.4 x 10-22 0.68  
(0.63, 0.74) 
3.0 x 10-22 0.71  
(0.64, 0.79) 
1.8 x 10-10 0.71  
(0.63, 0.79) 
1.7 x 10-10 
Andersen-Gill (II) 
0.68  
(0.61, 0.77) 
4.5 x10 
-11
 
0.68  
(0.61, 0.76) 
3.4 x 10
-11
 
0.71  
(0.62, 0.81) 
4.1 x 10
-7
 
0.71  
(0.62, 0.81) 
3.4 x 10
-7
 
Modified WLW  
First event 
0.76  
(0.69, 0.83) 
2.7 x 10
-8
 
0.75  
(0.68, 0.83) 
1.7 x 10
-8
 
0.74  
(0.65, 0.83) 
7.4 x 10
-7
 
0.74  
(0.65, 0.83) 
7.1 x 10
-7
 
Second event 
0.69  
(0.61, 0.78) 
4.6 x 10-9 
0.68  
(0.60, 0.77) 
3.1 x 10-9 
0.75  
(0.63, 0.89) 
0.0011 
0.75  
(0.63, 0.89) 
0.0011 
Third event 
0.70  
(0.60, 0.83) 
2.2 x 10
-5
 
0.70  
(0.60, 0.83) 
2.1 x 10
-5
 
0.79  
(0.65, 0.96) 
0.0170 
0.79  
(0.65, 0.96) 
0.0171 
Abbreviations: CI, confidence interval; HR, hazard ratio; RR, rate ratio; WLW, Wei-Lin-Weisfeld. 
 
Rate ratios (RR) are presented for results from negative binomial model; Hazard ratios (HR) are presented for results from Andersen 
Gill (I) model, Andersen Gill (II) model, and modified Wei-Lin-Weisfeld model. 
Unadjusted analyses only included treatment group in the model; Adjusted analyses also included stratification factors (cardiovascular 
risk category, geographic region, and use of ezetimibe) as covariate, in addition to treatment group in the model. 
 
Negative Binomial model (2-4).  
Andersen Gill (I) model is based on an intensity model with model-based variance estimate and was a pre-specified methodology (5). 
Andersen Gill (II) model is based on a proportional means model with cluster-robust standard errors, with the cluster set to the patient 
ID. This is an updated methodology (6). 
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Wei-Lin-Weisfeld is based on Li-Lagakos modification (7,8). In this modified WLW analysis, second event is defined as nonfatal 
second event or cardiovascular death, and third event is defined as nonfatal third event or cardiovascular death.  
Analyses are based on total adjudicated event dataset without accounting for multiple endpoints occurring in a single calendar day 
as a single event. 
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Online Figure 1. Study Design  
 
Abbreviations: CVD = cardiovascular disease, DM = diabetes mellitus, LDL-C = low density lipoprotein cholesterol, MI = myocardial 
infarction, TG =triglyceride. 
 
*Due to the variability of triglycerides, a 10% allowance existed in the initial protocol, which permitted patients to be enrolled with 
qualifying triglycerides ≥135 mg/dL. Protocol amendment 1 (May 2013) changed the lower limit of acceptable triglycerides from 150 
mg/dL to 200 mg/dL, with no variability allowance. 
 
†Median trial follow-up duration was 4.9 years (minimum 0.0, maximum 6.2 years) 
 
Reproduced from Bhatt DL, Steg PG, Miller M, et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N 
Engl J Med. 2019;380:11-22; permission pending.  
 
 
4 months,
12 months,
annually
Randomization End of Study
Screening Period Double-Blind Treatment/Follow-up Period
1:1
Randomization
with
continuation of
stable statin
therapy
(N=8179)
Lead-in
•
•
•
Key Inclusion Criteria
• Statin-treated men
and women ≥45 yrs
Established CVD
(~70% of patients) or
DM + ≥1 risk factor
TG ≥150 mg/dL and
<500 mg/dL*
LDL-C >40 mg/dL and
≤100 mg/dL
•
•
•
Icosapent
Ethyl
4 g/day
(n=4089)
Placebo
(n=4090)
Lab values Screening Baseline
Visit 1 2 3 4 5 6 7 Final Visit8 9
Months -1 Month 0 4 Every 12 months12
Up to 6.2 years†Year 0
Primary Endpoint
Time from
randomization to  the
first occurrence of
composite of CV death,
nonfatal MI, nonfatal
stroke, coronary
revascularization,
unstable angina
requiring hospitalization
4 months,
12 months,
annually
End-of-study
follow-up
visit
End-of-study
follow-up
visit
Statin
stabilization
Medication
washout
Lipid
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Online Figure 2. CONSORT Diagram 
 
* Early discontinuation from study (9.9% icosapent ethyl; 11.2% placebo) includes patients that 
discontinued after having a primary event (25 [0.6%] icosapent ethyl;52 [1.3% placebo) and 
prior to having an event (380 [9.3%icosapent ethyl; 408 [10.0%] placebo).  
Incl denotes inclusion, excl exclusion. 
 
Reproduced from Bhatt DL, Steg PG, Miller M, et al. Cardiovascular risk reduction with 
icosapent ethyl for hypertriglyceridemia. N Engl J Med. 2019;380:11-22; permission pending.
Screened 
N=19,212 
Randomized 
N=8179  
Screen Fails      N=11033* 
Incl./Excl. criteria not met              10,429  
Withdrawal of consent                         340 
Adverse event                                          13 
Primary prevention category closed      4        
Death                                                           5 
Lost to follow-up                                   108 
Enrollment closed                                     3 
Other                                                       135            
Icosapent Ethyl 
N=4089 (100%)  
Placebo 
N=4090 (100%)  
Completed Study      N=3684 (90.1%) 
       Completed final visit           3419 (83.6%) 
       Death before final visit             265 (6.5%)  
Early Discontinuation from Study N=405(9.9%)* 
     Withdrawal of consent                           281 (6.9%) 
     Investigator judgement                             12 (0.3%)                       
     Incomplete final visit                                   63 (1.5%) 
     Other                                                             49 (1.2%) 
Early Discontinuation from Study N=460 (11.2%)* 
     Withdrawal of consent                         297 (7.3%) 
     Investigator judgement                             12 (0.3%)                       
     Incomplete final visit                                 89 (2.2%) 
     Other                                                            62 (1.5%) 
*4 patients presented 2 screen failure reasons. 
Actual vs. potential follow-up time        92.9%  
Known vital status      4077 (99.7%) 
Actual vs. potential follow-up time (%)            93.6%  
Known vital status        4083 (99.9%) 
Completed Study      N=3630 (88.8%) 
       Completed final visit           3335 (81.5%) 
       Death before final visit             295 (7.2%) 
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Online Figure 3.  Total Events by Number of Events per Patient for the Primary Composite Endpoint and for Each 
Component  
 
Analyses are based on total adjudicated event dataset without accounting for multiple endpoints occurring in a single calendar day as a 
single event.
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Online Appendix for Recurrent Events Manuscript for JACC DLB 02 24 2019 
25 
CONFIDENTIAL 
Online Figure 4. Flow Chart of Total Primary (A) and Key Secondary (B) Composite 
Endpoint Events Accounting 
 
MI = myocardial infarction. Unstable angina indicates hospitalization for unstable angina. 
A
B
2622 events (1076 icosapent ethyl, 1546 placebo)
    2235 nonfatal (902 icospaent ethyl, 1333 placebo)
    387 fatal (174 icosapent ethyl, 213 placebo)
Used for analysis of primary outcome
8 events removed, same component occurred in 1 subject on same day
    7 coronary revascularization
    1 unstable angina
271 events removed, different component occurred in 1 subject on same day
  85 events occurring on same day as CV death, or resulting in CV death
    45 MI
    30 stroke
    9 coronary revascularization
    1 unstable angina
  186 events occurring on same day as another nonfatal event
    144 coronary revascularization + MI
    33 coronary revascularization + unstable angina
    3 coronary revascularization + stroke
    3 unstable angina + MI
    2 stroke + MI
    1 unstable angina on same day as a double coronary revascularization
8 events removed, occurring after a fatal MI or stroke, but before death
    3 additional stroke
    1 additional MI
    4 additional coronary revascularization
77 events removed, different component occurred in 1 subject on same day
  75 events occurring on same day as CV death, or resulting in CV death
    45 MI
    30 stroke
  2 nonfatal events occurring the same day
    2 stroke + MI
4 events occurring after a fatal MI or stroke, but before death
    3 additional stroke
    1 additional MI
2909 events (1185 icosapent ethyl, 1724 placebo)
    2522 nonfatal (1011 icosapent ethyl, 1511 placebo)
    387 fatal (174 icosapent ethyl, 213 placebo
1329 events (559 icosapent ethyl, 770 placebo)
    942 (nonfatal 385 icosapent ethyl, 557 placebo)
    387 fatal (174 icosapent ethyl, 213 placebo)
1325 events (558 icosapent ethyl, 767 placebo)
    938 nonfatal (384 icosapent ethyl, 554 placebo)
    387 fatal (174 icosapent ethyl, 213 placebo)
2901 events (1181 icosapent ethyl, 1720 placebo)
    2514 nonfatal (1007 icosapent ethyl, 1507 placebo)
    387 fatal (174 icosapent ethyl, 213 placebo)
Used in analysis of individual components
2630 events (1080 icosapent ethyl, 1550 placebo)
    2243 nonfatal (906 icosapent ethyl, 1337 placebo)
    387 fatal (174 icosapent ethyl, 213 placebo)
1406 events (590 icosapent ethyl, 816 placebo)
    1019 nonfatal (416 icosapent ethyl, 603 placebo)
    387 fatal (174 icosapent ethyl, 213 placebo)
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Online Figure 5. Distribution of First and Subsequent Primary Composite Endpoint Events in the Full Dataset for Patients 
Randomized 1:1 to Icosapent Ethyl Versus Placebo 
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Abbreviations: CI = confidence interval; HR = hazard ratio; RR = rate ratio.  
Hazard ratios (HR) and 95% confidence intervals (CI) for between treatment group comparisons were generated using Li-Lagakos-
modified Wei-Lin-Weissfeld (WLW) method for the 1st event, 2nd event, and 3rd event categories. Rate ratio (RR) and 95% CI for 
between group comparisons used a negative binomial model for additional events beyond 1st, 2nd, 3rd occurrences, i.e., 4th event or 
more and overall treatment comparison.  
Analyses are based on reduced dataset accounting for statistical handling of multiple endpoints occurring in a single calendar day by 
counting as a single event. 
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Methods: Study Design and Participants 
A complete description of methods for REDUCE-IT was previously published (Bhatt 2017).  Within this 
Appendix we summarize: select inclusion/exclusion criteria; the prespecified definitions for primary and 
key secondary endpoints, the total event analysis outcome measure and methodological details 
describing handling conventions for specific event combinations: 
Select Inclusion/Exclusion Criteria: 
The secondary prevention stratum consisted of patients with documented coronary artery 
disease (≥50% stenosis in at least two major epicardial coronary arteries with or without prior 
revascularization; prior MI; hospitalization for non-ST-segment elevation acute coronary 
syndrome with ST-segment deviation or positive biomarkers); documented cerebrovascular 
disease (prior ischemic stroke; symptomatic ≥50% carotid stenosis; asymptomatic carotid 
disease with ≥70% stenosis; history of carotid revascularization); or documented peripheral 
artery disease (ankle-brachial index <0.9 with symptoms of intermittent claudication; history of 
aorto-iliac or peripheral surgery or intervention). 
Primary prevention patients were to have no documented cardiovascular disease as defined 
above, to have diabetes, be ≥50 years old and have at least one of the following additional 
cardiovascular risk factors: increased age of ≥55 years if male or ≥65 years if female; cigarette 
smoker or stopped smoking within 3 months before first visit; blood pressure ≥140 mmHg 
systolic or ≥90 mmHg diastolic or on antihypertensive medication; HDL-cholesterol ≤40 mg/dL 
for men or ≤50 mg/dL for women; hs-CRP >3 mg/L; creatinine clearance >30 and <60 mL/min; 
non-proliferative retinopathy, pre-proliferative retinopathy, proliferative retinopathy, 
maculopathy, advanced diabetic eye disease or a history of photocoagulation; micro- or macro-
albuminuria; or asymptomatic ankle-brachial index <0.9. 
Exclusion criteria included (but were not limited to) severe heart failure, severe liver disease, 
poorly controlled hypertension, hemoglobin A1c levels >10.0%, planned coronary intervention, 
familial lipoprotein lipase deficiency, intolerance or hypersensitivity to statins, history of acute 
or chronic pancreatitis, and hypersensitivity to fish, shellfish, or ingredients of icosapent ethyl or 
placebo. All patients provided written informed consent.   
 
Primary Efficacy Endpoint:  
The primary efficacy endpoint is the time from randomization to the first occurrence of the 
composite of the following clinical events: 
• CV death 
• Nonfatal MI (including silent MI; ECGs will be performed annually for the detection of 
silent MIs) 
• Nonfatal stroke 
• Coronary revascularization  
• Unstable angina determined to be caused by myocardial ischemia by invasive/non-
invasive testing and requiring emergent hospitalization. 
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Key Secondary Efficacy Endpoint: 
The key secondary efficacy endpoint is the time from randomization to the first occurrence of 
the composite of: 
• CV death 
• Nonfatal MI (including silent MI) 
• Nonfatal stroke. 
Total event analysis outcome: 
The prespecified total event analysis was defined as the time from randomization to occurrence 
of the first and all recurrent major CV events defined as CV death, nonfatal MI (including silent 
MI), nonfatal stroke, coronary revascularization, or unstable angina determined to be caused by 
myocardial ischemia by invasive/non-invasive testing and requiring emergent hospitalization. 
Exploratory analyses of the total of first and subsequent events were also performed for the key 
secondary composite endpoint. 
All clinical endpoint events used in these efficacy analyses were adjudicated by an independent 
Clinical Endpoint Committee (CEC) whose members (specialists in cardiology or neurology) were 
blinded to treatment assignment. The CEC charter pre-specified handling conventions for 
specific event combinations. During adjudication, the CEC charter stipulated that cases of 
unstable angina leading to myocardial infarction within 48 hours were to be considered a single 
pathophysiologic process and counted as a single myocardial infarction.  Episodes of ischemic 
chest discomfort separated from the myocardial infarction by a quiescent period of more than 
48 hours were to be considered as two separate events. In cases of non-ST elevation myocardial 
infarctions and percutaneous coronary intervention, elevated baseline cardiac troponin values 
that were stable or falling and were followed by a rise in biomarkers of 20% or more were to 
constitute evidence of a second infarction due to the intervention itself. Additionally, patients 
with a transient ischemic attack (symptoms resolving within 24 hours) followed by a stroke 
(either ischemic or hemorrhagic) were to be considered as having two separate events.  An 
imaging study taken during the transient ischemic attack and which demonstrated necrosis or 
hemorrhage was to indicate a stroke instead of a transient ischemic attack even if symptoms 
resolved within 24 hours.  Lastly, conversion of an ischemic stroke to hemorrhagic stroke was to 
be considered a single event and a single pathophysiologic process. 
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REDUCE-IT Trial Investigators  
 
Steering Committee 
Deepak L. Bhatt MD, MPH (Chair and Principal Investigator), Christie M. Ballantyne MD, Eliot 
A. Brinton MD, Terry A. Jacobson MD, Michael Miller MD, Ph. Gabriel Steg MD, Jean‐Claude 
Tardif MD 
 
Global Principal Investigator 
Deepak L. Bhatt, MD, MPH, Professor of Medicine at Harvard Medical School, Executive 
Director of Interventional Cardiovascular Programs in the Heart and Vascular Center at Brigham 
and Women's Hospital, and the Principal Investigator and Steering Committee Chair for 
REDUCE-IT 
 
The Netherlands National Coordinating Investigator  
Fabrice MAC Martens, MD PhD, Board, Werkgroep Cardiologische centra Nederland (WCN; 
Dutch Network for Cardiovascular Research) 
 
The Netherlands National Leader Office  
Astrid Schut, MSc, Managing Director, Werkgroep Cardiologische centra Nederland (WCN; 
Dutch Network for Cardiovascular Research) 
 
Data Monitoring Committee 
Brian Olshansky MD (Chair), Mina Chung MD, Al Hallstrom PhD, Lesly Pearce MS (non‐
voting independent statistician) 
 
Independent Statistical Center Support for Data Monitoring Committee 
Cyrus Mehta PhD, Rajat Mukherjee PhD 
 
Clinical Endpoint Committee 
C Michael Gibson MD MS (Chair), Anjan K. Chakrabarti MD MPH, Eli V. Gelfand MD, Robert 
P. Giugliano MD SM, Megan Carroll Leary MD, Duane S. Pinto MD MPH, Yuri B. Pride MD 
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Amarin Operational and Statistical Team  
Substantial Support Across the Study  
Steven Ketchum PhD (President of R&D, Chief Scientific Officer, SVP) and team: Ramakrishna 
Bhavanthula MS, Gertrude Chester, Christina Copland PhD MPH, Katelyn Diffin MBA, Ralph 
Doyle Jr, Kurt Erz, Alex Giaquinto PhD, Paula Glanton MS, Angela Granger BA, Craig 
Granowitz MD PhD, Richard H Iroudayassamy, Lixia Jiao PhD, Rebecca Juliano PhD, James Jin 
PhD, Dimitry Klevak MS, Hardik Panchal MS, Robert Wang PhD, Shin-Ru Wang MS 
 
Study Design and Initiation 
Gerard Abate MD, Peggy J Berry MBA, Rene Braeckman PhD, Declan Doogan MD, Anne 
Elson, Amy HauptmannBaker, Isabel Lamela, Catherine Lubeck, Mehar Manku PhD, Sabina 
Murphy MPH, Monica Sanford, William Stirtan PhD, Paresh Soni MD PhD 
 
Additional Operational and Statistical Support 
Arnaud Bastien MD, Demetria Foster, Evangelito Gascon, Judith Johnson, Lasbert Latona MS, 
Sandra Palleja MD, Nelly Sanjuan, Jimmy Shi MS, William Stager PhD, Ahmed Youssef-Agha 
PhD, Julie Zhu MD 
 
Independent Statistical Support Center: Cytel, Inc. 
Leela Aertker MS, Suresh Ankolekar PhD, Lisa Goldberg MS, Natasa Rajicic ScD, Jianfen Shu 
PhD, Heng Zou MS 
 
Trial Operations 
Bioclinica (data management)  
Covance (central research laboratory)  
Syneos Health™ (formerly inVentiv Health; principal contract research organization) 
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